Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 717
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is NR11R12;
• 718
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl or aryl(C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• 719
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 720
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 721
• wherein R13 is an aryl, adamantyl, noradamantyl, C3-C10 cycloalkyl, heteroaryl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 722
• wherein Q2 is
• 723
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 724
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subjects depression wherein the compound has the structure:

• 725
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 726
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is (C(R19)2)m—N(R16)2;
• wherein Z is C3-C10cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)]-O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein q is an integer from 2 to 4 inclusive or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 740
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is;
• NR11R12;
• 741
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl, or aryl (C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C3-C10 cycloalkyl, heteroaryl, aryl, aryl(C1-C6)alkyl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 742
• wherein Q2 is
• 743
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 744
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6, cycloalkyl, (C(R19)2)mN(R16)2 or (C(R19)2)m—Z;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl, or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 745
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is NR11R12;
• 746
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl or aryl(C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• 747
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 748
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 749
• wherein R13 is an aryl, adamantyl, noradamantyl, C3-C10cycloalkyl, heteroaryl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 750
• wherein Q2 is
• 751
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 752
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z , or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 753
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 754
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is (C(R19)2)m—N(R16)2;
• wherein Z is C3-C10cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• or
• a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 768
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is;
• NR11R12;
• 769
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl, or aryl (C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C3-C10cycloalkyl, heteroaryl, aryl, aryl(C1-C6)alkyl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 770
• wherein Q2 is
• 771
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 772
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, (C(R19)2)mN(R16)2 or (C(R19)2)m—Z;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl, or aryl(C1-C6)alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• wherein U is O, —NR16, S, C(R17) 2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• or
• a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 773
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is NR11R12;
• 774
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl or aryl(C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• 775
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 776
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 777
• wherein R13 is an aryl, adamantyl, noradamantyl, C3-C10 cycloalkyl, heteroaryl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 778
• wherein Q2 is
• 779
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 780
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 781
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 782
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl (C1-C6) alkyl;
• wherein Y is NR14R15;
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is (C(R19)2)m—N(R16)2;
• wherein Z is C3-C10cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C1-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• or
• a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 791
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is;
• NR11R12;
• 792
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl, or aryl (C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, adamantyl, noradamantyl, C3-C10cycloalkyl, heteroaryl, aryl, aryl(C1-C6) alkyl, Q1 or Q2;
• wherein aryl may be substituted with one or more C1-C10 straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 793
• wherein Q2 is
• 794
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 795
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, (C(R19)2)mN(R16)2 or (C(R19)2)m—Z;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)]-O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl, or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• or
• a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 796
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is NR11R12;
• 797
• wherein R11 is H, straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, aryl or aryl(C1-C6)alkyl;
• wherein R12 is straight chained or branched C1-C7 alkyl, (CH2)q—O—(CH2)m—CH3, or —(CH2)m—Z;
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• 798
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 799
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 800
• wherein R13 is an aryl, adamantyl, noradamantyl, C3-C10 cycloalkyl, heteroaryl, Q1 or Q2;
• wherein aryl may be substituted with one or more CL-Clo straight chained or branched alkyl, aryl, heteroaryl, or N(R19)—Z;
• wherein Q1 is
• 801
• wherein Q2 is
• 802
• wherein each J is independently O, S, C(R22)2 or NR4;
• wherein R4 is —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein Y is NR14R15;
• 803
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is straight chained or branched C3-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C2-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein R18 is straight chained or branched C1-C6 alkyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each R22 is independently H, F, Cl or C1-C4 straight chained or branched alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein p is an integer from 0 to 2 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• wherein t is 1 or 2;
• or
• a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 804
• wherein W is H, —F, —Cl, —Br, —I, CN, methyl, ethyl, propyl, methoxy or ethoxy;
• wherein X is N(CH3)2 or
• 805
• wherein R13 is a bicyclic alkyl ring system, aryl or aryl(C1-C6)alkyl;
• wherein Y is NR14R15;
• wherein R14 is H, straight chained or branched C1-C6 alkyl, (CH2)q—O—(CH2)m—CH3, C3-C6 cycloalkyl, or (C(R19)2)m—Z;
• wherein R15 is (C(R19)2)m—N(R16)2;
• wherein Z is C3-C10 cycloalkyl, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein each R17 is independently H;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, —COOR21, straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)m—O—(CH2)m—CH3;
• wherein each R19 is independently H, or straight chained or branched C1-C6 alkyl;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein q is an integer from 2 to 4 inclusive;
• or
• a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 814
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl (C1-C6) alkyl;
• wherein A is A′, Q3, Q4, Q5, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl, heteroaryl (C1-C6) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl;
• or (CHR17)—(CHR17)n—Z;
• wherein A′ is
• 815
• wherein Q3 is
• 816
• wherein Q4 is
• 817
• wherein Q5 is
• 818
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein q is an integer from 2 to 4 inclusive;
• wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 819
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 820
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• 821
• wherein A′ is
• 822
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4) 2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein n is an integer from 1 to 4 inclusive;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 823
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• wherein A′ is
• 824
• wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 825
• wherein n is an integer from 1 to 4 inclusive;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from depression which comprises administering to the subject an amount of compound effective to treat the subject's depression wherein the compound has the structure:

• 826
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is Q3, Q4, Q5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR17)—(CHR17)n—Z;
• wherein Q3 is
• 827
• wherein Q4 is
• 828
• wherein Q5 is
• 829
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• wherein q is an integer from 2 to 4 inclusive;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 840
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, Q3, Q4, Q5, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl, heteroaryl (C1-C6) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl;
• or (CHR17)—(CHR17)n—Z;
• wherein A′ is
• 841
• wherein Q3 is
• 842
• wherein Q4 is
• 843
• wherein Q5 is
• 844
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6, aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)m—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, (CH2)m—Z, or (CH2)q—O—(CH2)m—O—CH3;
• wherein q is an integer from 2 to 4 inclusive;
• wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 845
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 846
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• wherein A′ is
• 847
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4) 2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein n is an integer from 1 to 4 inclusive;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 848
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1 Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl(C1-C6)alkyl;
• wherein A′ is
• 849
• wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 850
• wherein n is an integer from 1 to 4 inclusive;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A method of treating a subject suffering from anxiety which comprises administering to the subject an amount of compound effective to treat the subject's anxiety wherein the compound has the structure:

• 851
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is Q3, Q4, Q5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR17)—(CHR17)n—Z;
• wherein Q3 is
• 852
• wherein Q4 is
• 853
• wherein Q5 is
• 854
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• wherein q is an integer from 2 to 4 inclusive;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 865
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, Q3, Q4, Q5, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl, heteroaryl (C1-C6) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl;
• or (CHR17)—(CHR17)n—Z;
• wherein A′ is
• 866
• wherein Q3 is
• 867
• wherein Q4 is
• 868
• wherein Q5 is
• 869
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6, aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)nO—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein q is an integer from 2 to 4 inclusive;
• wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 870
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 871
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• wherein A′ is
• 872
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein n is an integer from 1 to 4 inclusive;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 873
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• wherein A′ is
• 874
• heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 875
• wherein n is an integer from 1 to 4 inclusive;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the structure:

• 876
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C5)alkyl;
• wherein A is Q3, Q4, Q5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR17)—(CHR17)n—Z;
• wherein Q3 is
• 877
• wherein Q4 is
• 878
• wherein Q5 is
• 879
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21—OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• wherein q is an integer from 2 to 4 inclusive;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• or a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 886
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′, Q3, Q4, Q5, straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6) alkyl, heteroaryl (C1-C6) alkyl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl;
• or (CHR17)—(CHR17)n—Z;
• wherein A′ is
• 887
• wherein Q3 is
• 888
• wherein Q4 is
• 889
• wherein Q5 is
• 890
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein each R17 is independently H;
• straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl (C1-C6) alkyl;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10 cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein q is an integer from 2 to 4 inclusive;
• wherein B is aryl, heteroaryl, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein a tricyclic heteroaryl is a fused three member aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 891
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 892
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C13-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′ straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl(C1-C6)alkyl;
• wherein A′ is
• 893
• wherein R1 and R2 are each independently H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, or —CN;
• wherein R3 is H, straight chained or branched C1-C7 alkyl, —F, —Cl, —Br, —I, —NO2, —CN, —OR6 aryl or heteroaryl;
• wherein R5 is straight chained or branched C1-C7 alkyl, —N(R4)2, —OR6 or aryl;
• wherein R6 is straight chained or branched C1-C7 alkyl or aryl;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• wherein n is an integer from 1 to 4 inclusive;
• or a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 894
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is A′ straight chained or branched C1-C7 alkyl, aryl, heteroaryl, aryl(C1-C6)alkyl or heteroaryl (C1-C6) alkyl;
• wherein A′ is
• 895
• wherein B is aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, tricyclic heteroaryl or Q6;
• wherein a tricyclic heteroaryl is a fused three ring aromatic system in which one or more of the rings is heteroaryl;
• carbazole;
• or acridine;
• wherein Q6 is
• 896
• wherein n is an integer from 1 to 4 inclusive;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• or a pharmaceutically acceptable salt thereof.

A compound having the structure:

• 897
• wherein each of Y1, Y2, Y3, and Y4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR4, —SR4, —OCOR4, —COR4, —NCOR4, —N(R4)2, —CON(R4)2, or —COOR4;
• aryl or heteroaryl;
• or any two of Y1, Y2, Y3 and Y4 present on adjacent carbon atoms can constitute a methylenedioxy group;
• wherein each R4 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl, aryl or aryl(C1-C6)alkyl;
• wherein A is Q3, Q4, Q5, aryl substituted with an aryl or heteroaryl, heteroaryl substituted with an aryl or heteroaryl, or (CHR17)—(CHR17)n—Z;
• wherein Q3 is
• 898
• wherein Q4 is
• 899
• wherein Q5 is
• 900
• wherein each R17 is independently H;
• straight chained or branched C2-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)n—O—(CH2)m—CH3;
• wherein each R20 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl or C5-C7 cycloalkenyl;
• —F, —Cl, —Br, or —I;
• —NO2;
• —N3;
• —CN;
• —OR21, —OCOR21, —COR21, —NCOR21, —N(R21)2, —CON(R21)2, or —COOR21;
• aryl or heteroaryl;
• or two R20 groups present on adjacent carbon atoms can join together to form a methylenedioxy group;
• wherein each R21 is independently —H;
• straight chained or branched C1-C7 alkyl, monofluoroalkyl or polyfluoroalkyl;
• straight chained or branched C2-C7 alkenyl or alkynyl;
• C3-C7 cycloalkyl, C5-C7 cycloalkenyl or aryl;
• wherein each R22 is independently H, F, Cl, or straight chained or branched C1-C4 alkyl;
• wherein q is an integer from 2 to 4 inclusive;
• wherein each m is an integer from 0 to 4 inclusive;
• wherein each n is an integer from 1 to 4 inclusive;
• wherein each p is an integer from 0 to 2 inclusive;
• wherein U is O, —NR16, S, C(R17)2, or —NSO2R16;
• wherein Z is C3-C10cycloalkyl, C4-C7 cyclic ether, C4-C7 cyclic thioether, aryl, or heteroaryl;
• wherein R16 is straight chained or branched C1-C7 alkyl, straight chained or branched C1-C7 monofluoroalkyl, straight chained or branched C1-C7 polyfluoroalkyl, straight chained or branched C2-C7 alkenyl, straight chained or branched C2-C7 alkynyl, C5-C7 cycloalkenyl, —(CH2)m—Z, or (CH2)q—O—(CH2)m—CH3;
• wherein B is aryl, or heteroaryl;
• provided however, if B is aryl or heteroaryl the carbon atom or carbon atoms ortho to the nitrogen atom of the imine bond may only be substituted with one or more of the following —F, —Cl, —Br, —I, —CN, methyl, ethyl or methoxy;
• or a pharmaceutically acceptable salt thereof.

A method of treating depression in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:

• (a) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GALL receptor;
• (b) (1) the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase A greater than 50 percent, at a concentration of 10 μM;
• and
• (2) the GAL3 receptor antagonist does not inhibit the activity of central monoamine oxidase B greater than 50 percent, at a concentration of 10 μM;
• and
• (c) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters:
• serotonin transporter, norepinephrine transporter, and dopamine transporter.

A method of treating anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist, wherein:

• (a) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to the human GAL1 receptor;
• and
• (b) the GAL3 receptor antagonist binds to the human GAL3 receptor with a binding affinity at least ten-fold higher than the binding affinity with which it binds to each of the following transporters:
• serotonin transporter, norepinephrine transporter, and dopamine transporter.